Larimar Therapeutics recently completed an upsized US$100,000,000 follow-on equity offering at US$5.00 per share, shortly after the FDA granted Breakthrough Therapy Designation to its lead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results